In recognition of Men’s Health Month, UVA Cancer Center is expanding “Stay in the Game,” a community-centered program to raise awareness across Virginia about prostate cancer and the importance of early screening.
GammaTile showed superiority in the primary endpoint of the study. Patients who received GammaTile lived longer without tumor regrowth, reducing the risk of either tumor recurrence or death by 50% reduction compared to standard of care, according to interim results from the ROADS clinical trial, which evaluated GammaTile versus standard of care in patients with operable, newly diagnosed brain metastases.
